Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience

被引：0

作者：

Darcin, Tahir ^{[1
]}

Yigenoglu, Tugce Nur ^{[1
]}

Sahin, Derya ^{[1
]}

Bakirtas, Mehmet ^{[1
]}

Basci, Semih ^{[1
]}

Merdin, Alparslan ^{[1
]}

Yildiz, Jale ^{[1
]}

Ulu, Bahar Uncu ^{[1
]}

Tetik, Aysegul ^{[1
]}

Iskender, Dicle ^{[1
]}

Cakar, Merih Kizil ^{[1
]}

Dal, Mehmet Sinan ^{[1
]}

Altuntas, Fevzi ^{[1
,2
]}

机构：

[1] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol, Stem Cell Transplantat Unit, Ankara, Turkey

[2] Yildirim Beyazit Univ, Fac Med, Dept Internal Med, Div Hematol, Ankara, Turkey

来源：

关键词：

polatuzumab vedotin; relapsed/refractory NHL; combined chemotherapy; ABCL; aggressive B-cell lymphoma; case;

D O I：

10.1016/j.clml.2019.07.155

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-244

引用

页码：S249 / S250

页数：2